SHANGHAI (Reuters) – China is looking to speed up approvals for new drugs and plans to accept data from clinical trials carried out overseas, a potential boon for international drugmakers and patients who often face lengthy delays for new medicines to reach the market.
About the author
← Uber suspends unlicensed service in Norway in change of tack Greek archaeologists clear way for Hellenikon resort →
March 15, 2017 Comments Off on Marx’s German birthplace to accept controversial Chinese statue
February 11, 2017 Comments Off on Mexico Now Refusing To Accept Trump Deportees, Hold That America Must Provide Payment Instead